MediSieve

MediSieve is a private, pre-revenue biotech founded in 2014, pioneering a magnetic blood filtration platform. Its core technology involves functionalizing magnetic beads to bind specific targets in the blood, which are then removed extracorporeally via a magnetic filter. The pipeline targets acute hyperinflammation (e.g., sepsis, CRS), severe malaria, and enabling AAV gene therapies by depleting neutralizing antibodies. The company represents a novel therapeutic device approach in hematology and critical care.

Magnetic Blood Filtration system using nanoengineered magnetic particles functionalized with targeting ligands to selectively bind and remove specific pathogens, cells, or molecules from blood via an extracorporeal magnetic filter.

Faces competition from other blood purification technologies (e.g., CytoSorb's adsorbent cartridge, traditional plasmapheresis) and from drug-based approaches (e.g., IL-6 inhibitors). Its key differentiator is the claimed high selectivity of its magnetic capture platform.